<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097668</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-MS-1467-002</org_study_id>
    <nct_id>NCT01097668</nct_id>
  </id_info>
  <brief_title>ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apitope Technology (Bristol) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aptiv Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinStar, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Apitope Technology (Bristol) Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with
      relapsing forms of multiple sclerosis. This will be an open label upward dose titration
      involving injections on 9 occasions, each two weeks apart. After dosing is complete there
      will be a 22 week follow up period. Blood samples will be drawn throughout the study to
      monitor safety and the body's response to the injections and MRI scans will be performed on
      several occasions to follow the course of the multiple sclerosis during the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>48 weeks</time_frame>
    <description>Occurrence of treatment emergent Adverse Events (AE), Serious Adverse Events, and laboratory abnormalities up to week 48 compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of ATX-MS-1467 on Brain Magnetic Resonance Imaging (MRI).</measure>
    <time_frame>16 and 20 weeks</time_frame>
    <description>Number of new or persisting Gadolinium-enhancing lesions at week 16 and 20 when compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Intradermal injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections will be given by the intradermal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections will be given by the subcutaneous route</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATX-MS-1467</intervention_name>
    <description>Disease specific immune modulating treatment for multiple sclerosis</description>
    <arm_group_label>Intradermal injection</arm_group_label>
    <arm_group_label>Subcutaneous injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients who have definite relapsing multiple sclerosis disease as defined by the
             McDonald criteria (McDonald et al., 2001 and 2005) and as assessed by a neurologist.

             2. HLA DRB1*15 positive.

             3. High baseline levels of T-cell proliferation in response to myelin basic protein,
             defined as &gt;1000 cpm with a &gt;3 stimulation index compared to background.

             4. Disease duration equal to or less than 10 years (from the first clinical event).

             5. At least one documented relapse in the previous 12 months or two relapses within
             the previous 24 months prior to screening.

             6. Must be in a clinically stable or improving neurological state during the 28 days
             preceding Screening.

             7. EDSS score &lt; 5.5.

        Exclusion Criteria:

          -  1. Subjects treated with β-interferon, plasma exchange, intravenous gamma globulin
             within the 3 months prior to Study Day 1 2. Subjects treated with glatiramer acetate
             at any time in the past 3. Subjects who have been treated with parenteral steroids or
             adrenocorticotropic hormone within 3 months days prior to Study Day 1 4. Prior
             treatment with: cytotoxic agents (including but not limited to cladribine,
             mitoxantrone, cyclophosphamide, azathioprine, methotrexate), fingolimod, laquinimod,
             teriflunomide, total lymphoid irradiation, stem cell or bone marrow transplantation,
             or monoclonal antibody therapy (including natalizumab, daclizumab, alemtuzumab) 5.
             Prior use of disease related T-cell vaccine or peptide-tolerising agent to treat MS 6.
             Use of any investigational drug or experimental procedure within 6 months prior to
             Study Day 1 including cytokine or anti-cytokine therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Chataway</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital for Neurology and Neurosurgery, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;City Clinical Hospital #3&quot;, Department of neurology</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution &quot;Republican Clinical Hospital of rehabilitation treatment of Ministry of Healthcare of Tatarstan Republic&quot;, Republican clinicodiagnostic center of demyelinating diseases of Ministry of Healthcare of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;1st Moscow State Medical University n.a. I.M. Sechenov of Ministry of Healthcare and Social Development of the Russian Federation, Department of new drugs research</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution 'Rostov Regional Clinical Hospital' Center of Neurology</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;International Clinic MEDEM&quot;, Department of functional diagnostics</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;St. Petersburg State Medical University n.a. I.V. Pavlov of Roszdrav&quot;, Department of neurology with clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Samara Regional Clinical Hospital n.a. M.I. Kalinin&quot;, Department of neurosurgery</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Smolensk State Medical Academy of Roszdrav&quot;, Department of neurology and neurosurgery based at State Healthcare Institution &quot;Smolensk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution &quot;City multifield hospital #2&quot;, Department of neurology #2</name>
      <address>
        <city>St Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Science &quot;Institute of Human Brain of RAS&quot;, Neuroimmunology Laboratory</name>
      <address>
        <city>St Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Staffordshire Royal Infirmary</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Medical School</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2 JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.apitope.com</url>
    <description>sponsor</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>December 23, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2015</results_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening and study procedures were performed at hospital clinics within the United Kingdom and Russian Federation.</recruitment_details>
      <pre_assignment_details>Subjects were human lymphocyte antigen (HLA)-DRB1*15 positive with relapsing-remitting multiple sclerosis as defined by the McDonald criteria and as assessed by a neurologist.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intradermal Injection</title>
          <description>Upward titration over 4 dose levels (injections of 25, 50, 100 and 400 ug) of ATX MS 1467 followed by injections of 800 ug injected on 5 occasions. All injections were administered at intervals of 14±3 days.</description>
        </group>
        <group group_id="P2">
          <title>Subcutaneous Injection</title>
          <description>Upward titration over 4 dose levels (injections of 25, 50, 100 and 400 ug) of ATX MS 1467 followed by injections of 800 ug injected on 5 occasions. All injections were administered at intervals of 14±3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 20</title>
              <participants_list>
                <participants group_id="P1" count="21">Patient evaluability time point = week 20</participants>
                <participants group_id="P2" count="22">Patient evaluability time point = week 20</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 48</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>&gt;=18 and &lt;=55 years Gender, female and male</population>
      <group_list>
        <group group_id="B1">
          <title>Intradermal Injection</title>
          <description>Injections of ATX-MS-1467 given by the intradermal route</description>
        </group>
        <group group_id="B2">
          <title>Subcutaneous Injection</title>
          <description>Injections of ATX-MS-1467 given by the subcutaneous route</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" lower_limit="22" upper_limit="53"/>
                    <measurement group_id="B2" value="31.6" lower_limit="18" upper_limit="52"/>
                    <measurement group_id="B3" value="32.3" lower_limit="18" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability</title>
        <description>Occurrence of treatment emergent Adverse Events (AE), Serious Adverse Events, and laboratory abnormalities up to week 48 compared to baseline.</description>
        <time_frame>48 weeks</time_frame>
        <population>The Safety population will be denoted as the ‘ITT population’ for the summarisation of safety endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Intradermal Injection</title>
            <description>Injections of ATX-MS-1467 administered by the intradermal route</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Injection</title>
            <description>Injections of ATX-MS-1467 administered by the subcutaneous route</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Occurrence of treatment emergent Adverse Events (AE), Serious Adverse Events, and laboratory abnormalities up to week 48 compared to baseline.</description>
          <population>The Safety population will be denoted as the ‘ITT population’ for the summarisation of safety endpoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ATX-MS-1467 on Brain Magnetic Resonance Imaging (MRI).</title>
        <description>Number of new or persisting Gadolinium-enhancing lesions at week 16 and 20 when compared to baseline.</description>
        <time_frame>16 and 20 weeks</time_frame>
        <population>ITT population at week 16 and 20 n=21 (Intradermal injection) ITT population at week 16 and 20 n=22 (Subcutaneous injection) MRI population at week 16 and 20 n=17 (Intradermal injection) MRI population at week 16 and 20 n=20 (Subcutaneous injection)</population>
        <group_list>
          <group group_id="O1">
            <title>Intradermal</title>
            <description>Injections of ATX-MS-1467 administered by intradermal route</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Injection</title>
            <description>Injections of ATX-MS-1467 administered by subcutaneous route</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ATX-MS-1467 on Brain Magnetic Resonance Imaging (MRI).</title>
          <description>Number of new or persisting Gadolinium-enhancing lesions at week 16 and 20 when compared to baseline.</description>
          <population>ITT population at week 16 and 20 n=21 (Intradermal injection) ITT population at week 16 and 20 n=22 (Subcutaneous injection) MRI population at week 16 and 20 n=17 (Intradermal injection) MRI population at week 16 and 20 n=20 (Subcutaneous injection)</population>
          <units>MRI lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT poulation at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="1.83" upper_limit="13.93"/>
                    <measurement group_id="O2" value="2.09" lower_limit="0.76" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT population at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.33" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.85" lower_limit="1.00" upper_limit="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT population at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="0.63" upper_limit="4.34"/>
                    <measurement group_id="O2" value="1.47" lower_limit="0.85" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI population at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="1.08" upper_limit="10.75"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.79" upper_limit="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI population at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.28" upper_limit="1.89"/>
                    <measurement group_id="O2" value="1.71" lower_limit="0.93" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRI population at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="0.48" upper_limit="4.73"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.68" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of the baseline 'ITT population' MRI data with week 16 data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>negative binomial model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of the baseline 'MRI population' data with data from week 16.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>negative binomial model</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected over the course of the study = 52 weeks</time_frame>
      <desc>Adverse Events were recorded in the Case Report Form and characterised by severity, relationship to IMP,outcome, action taken, onset and resolution date and seriousness. Occurrences of Multiple Sclerosis relapses were recorded as Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intradermal Injection - Treatment Emergent</title>
          <description>Injections will be administered by the intradermal route</description>
        </group>
        <group group_id="E2">
          <title>Subcutaneous Injection - Treatment Emergent</title>
          <description>Injections will be administered by the subcutaneous route</description>
        </group>
        <group group_id="E3">
          <title>Intradermal Injection - Non Treatment Emergent</title>
          <description>Follow-up period</description>
        </group>
        <group group_id="E4">
          <title>Subcutaneous Injection - Non Treatment Emergent</title>
          <description>Follow-up period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <description>Treatment emergent = onset date is on or after the date of first dosing with IMP, and the onset date does not occur after the date of the Week 20 visit.
Non-treatment emergent = onset date is after the date of the Week 20 visit.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Adverse Events of moderate intensity.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reactions</sub_title>
                <description>Treatment Emergent Adverse Event of mild to moderate intensity.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-peptide Antibody response</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Nasopharyngitis of mild to moderate intensity was experienced by 3 patients at the 800 μg dose level only (weeks 14 and 16).</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <description>Emergent Adverse Events of moderate intensity.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Adverse Events of mild intensity.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Adverse Events of mild to moderate intensity.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <description>Adverse Events of moderate intensity. The number of MS relapses was not unexpected for this population.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <description>Subject had a TEAE assessed as moderate in severity one week after the week 14 dose. This was located on the subject's back and arm whilst the injection was on the abdomen.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If the Investigator drafts a publication, he/she agrees to send it to Apitope for review and comment before its submission to the journal. If Apitope considers that the proposed publication contains patentable material or information which should be protected as valuable confidential information, Apitope reserves the right to delay submission to the journal until patent applications have been filed and/or require the deletion of the confidential information from the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Executive Officer</name_or_title>
      <organization>Apitope Technology (Bristol) Ltd</organization>
      <phone>+44(0)117 3707720</phone>
      <email>keith.martin@apitope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

